The completed Phase 3 study, XTEND‐1 (NCT04161495), demonstrated that once‐weekly efanesoctocog alfa prophylaxis provided superior bleed prevention compared with prior FVIII prophylaxis in adults and adolescents with severe hemophilia A and was well tolerated [19]. This evidence concerns the gene F8 and hemophilia A.